No Data
HC Wainwright & Co. Reiterates Buy on LAVA Therapeutics, Maintains $6 Price Target
LAVA Therapeutics Analyst Ratings
H.C. Wainwright Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
H.C. Wainwright analyst Arthur He CFA maintains $LAVA Therapeutics(LVTX.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 47.8%
Little Excitement Around LAVA Therapeutics N.V.'s (NASDAQ:LVTX) Revenues As Shares Take 26% Pounding
Analysts Offer Insights on Healthcare Companies: Aldeyra Therapeutics (ALDX), LAVA Therapeutics (LVTX) and Crinetics Pharmaceuticals (CRNX)
JMP Securities Maintains LAVA Therapeutics(LVTX.US) With Buy Rating, Maintains Target Price $6
JMP Securities analyst Reni Benjamin maintains $LAVA Therapeutics(LVTX.US)$ with a buy rating, and maintains the target price at $6.According to TipRanks data, the analyst has a success rate of 35.5%